YOLFTbeta
67

UnicoCell Biomed Co., Ltd.

6794 · TW · Healthcare / Biotechnology

65.80TWD+1.30 (+2.02%)

Price History

Full chart

Market Stats

Previous Close64.50
Open64.80
Day Range64.50 – 67.20
52-Week Range65.60 – 93.20
Volume82.00K
Market Cap5.02B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.66
Dividend Yield0.00%
Beta-0.22
50-Day Avg74.73
200-Day Avg80.95

About

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell count and viability tests, as well as contract development and manufacturing organization (CDMO) services for cell-based products. UnicoCell Biomed Co., Ltd. was founded in 2011 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Yi-Pei Hung
  • HeadquartersNo. 13-20, Minquan East Road, Taipei, Taiwan, 11494, Taiwan
  • Websitehttps://www.unicocell.com

Leadership

  • Mr. Yi-Pei HungGeneral Manager
  • Pei-Lin ChenCFO & Corporate Governance Officer
  • Mr. Lin Chen-YuAssistant Vice President
  • Ms. Ting WangAssistant Vice President
  • Jui-Yu LiuAccounting Supervisor & Chief Internal Auditor

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.99M5.49M15.74M3.98M8.18M14.40M24.59M31.88M30.10M
Growth (%)--8.25%+186.54%-74.70%+105.35%+76.07%+70.79%+29.66%-5.58%
Cost of Revenue1.04M1.29M3.25M1.64M2.35M6.20M6.69M11.31M30.32M
Gross Profit4.95M4.20M12.48M2.34M5.83M8.20M17.90M20.57M-221.00K
Gross Margin82.68%76.44%79.32%58.71%71.32%56.93%72.78%64.52%-0.73%
Operating Expense49.20M73.21M113.53M110.60M93.17M100.31M114.18M123.49M130.06M
Operating Income-44.25M-69.01M-101.04M-108.27M-87.34M-92.11M-96.28M-102.92M-130.28M
Operating Margin-739.17%-1256.52%-642.07%-2718.86%-1068.08%-639.78%-391.56%-322.82%-432.77%
EBITDA-39.44M-63.61M-79.10M-84.60M-59.45M-65.63M-56.28M-64.03M-109.73M
EBITDA Margin-658.79%-1158.16%-502.65%-2124.64%-726.98%-455.85%-228.87%-200.83%-364.51%
Net Income-42.92M-40.51M-100.94M-109.21M-86.37M-91.16M-84.11M-93.07M-114.84M
Net Income Margin-717.07%-737.58%-641.41%-2742.57%-1056.30%-633.15%-342.06%-291.94%-381.48%
R&D49.20M66.21M93.50M91.75M69.87M74.91M82.78M88.64M92.44M
R&D as % of Total Revenue821.85%1205.64%594.14%2304.24%854.46%520.30%336.66%278.04%307.08%
Interest Expense--1.22M944.00K656.00K1.26M1.45M1.47M1.34M
Interest Expense % of Total Revenue--7.77%23.71%8.02%8.72%5.91%4.60%4.45%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets141.49M286.05M356.17M391.22M297.71M414.31M685.93M777.89M946.01M
Total Liabilities4.16M13.07M61.86M47.81M34.71M80.46M89.49M93.28M80.58M
Total Equity137.33M272.98M294.32M343.41M263.00M333.85M596.44M684.61M865.43M
Cash122.88M252.97M225.85M222.02M130.85M53.64M19.90M9.57M40.99M
Total Debt--44.68M34.03M21.58M66.59M74.33M68.24M62.02M
Net Debt-122.88M-252.97M-181.18M-187.99M-109.27M12.95M54.43M58.66M21.02M

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-42.40M-58.01M-77.17M-92.16M-61.71M-63.60M-65.55M-61.52M-91.31M
Investing Cash Flow-1.94M-14.90M-50.37M-57.12M-23.80M-164.99M-307.20M-122.35M-173.49M
Financing Cash Flow-203.00M110.39M145.44M-5.66M151.38M339.01M173.54M296.07M
Capital Expenditure1.94M10.39M50.77M56.85M23.99M14.61M15.98M5.71M5.50M
Free Cash Flow-44.34M-68.40M-127.94M-149.01M-85.70M-78.21M-81.53M-67.22M-96.81M
FCF to OCF104.57%117.91%165.78%161.69%138.88%122.97%124.38%109.27%106.02%

Key Statistics & Ratios

Market Cap5.02B
Enterprise Value4.12B
Trailing P/E0.00
Forward P/E0.00
Price / Sales223.54
Price / Book5.83
EPS-1.66
Book Value12.86
Revenue (TTM)22.46M
Gross Profit (TTM)12.93M
EBITDA-111.23M
Profit Margin0.00%
Operating Margin-630.69%
Return on Equity-13.14%
Return on Assets-8.89%
Shares Outstanding63.64M
Shares Float26.51M
Beta-0.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%